Skip to main content

Advertisement

SpringerLink
Log in

Discontinuation of tyrosine kinase therapy in CML

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Over the past decade, a broad array of drugs designed to selectively inhibit protein tyrosine kinases (tyrosine kinase inhibitors or TKIs) have emerged as novel therapies for cancer patients. Chronic myeloid leukemia (CML) is one of the best examples of successful targeted therapy with a TKI. The overall survival of CML patients who respond to treatment is close to that of the healthy population. The response in many patients is so profound that it is possible to consider stopping their treatment and with time, the number of patients in this group has increased to the point where the issue of treatment cessation has become of utmost importance. This has led to the development of a new concept in the evaluation of CML entitled treatment-free remission. It will be the criterion to evaluate the success of future clinical trials, especially if we want to improve the management of the disease to the point where we can claim to have cured CML.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. National Comprehensive Cancer Network (2012) Chronic Myelogenous Leukemia. NCCN Clinical Practice Guidelines in Oncology; v1.2013

  2. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872–884

    Article  CAS  PubMed  Google Scholar 

  3. Rea D, Rousselot P, Guilhot J, Guilhot F, Mahon FX (2012) Curing chronic myeloid leukemia. Curr Hematol Malig Rep 7:103–108

    Article  PubMed  Google Scholar 

  4. Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58–60

    Article  CAS  PubMed  Google Scholar 

  5. Mahon FX (2012) Is going for cure in chronic myeloid leukemia possible and justifiable? Hematol Am Soc Hematol Educ Program 2012:122–128

    Google Scholar 

  6. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini F et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035

    Article  CAS  PubMed  Google Scholar 

  7. Mahon F, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE et al (2013) Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM Study. Blood (ASH Annual Meeting Abstracts);122, [abstract 255]

  8. Ross DM, Branford S, Seymour JF et al (2010) Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24:1719–1724

    Article  CAS  PubMed  Google Scholar 

  9. Ross DM, Branford S, Seymour JF, Arthur C, Schwarer AP, Dang P et al (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515–522

    Article  CAS  PubMed  Google Scholar 

  10. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T et al (2012) Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica 97:903–906

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Cortes J, O’Brien S, Kantarjian H (2004) Discontinuation of imatinib therapy after achieving a molecular response. Blood 104:2204–2205

    Article  CAS  PubMed  Google Scholar 

  12. Mauro MJ, Druker BJ, Marziaz RT (2004) Divergent clinical outcome in twp CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 28(S1):S71–S73

    Article  CAS  PubMed  Google Scholar 

  13. Merante S, Orlandi E, Bernasconi P et al (2005) Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 90:979–981

    PubMed  Google Scholar 

  14. Michor F, Hughes TP, Iwasa Y et al (2005) Dynamics of chronic myeloid leukaemia. Nature 435:1267–1270

    Article  CAS  PubMed  Google Scholar 

  15. Mahon FX, Nicolini F, Noël MP, Escoffre M, Charbonnier A, Rea D, Dubruille V, Varet B, Legros L, Guerci A, Etienne G, Guilhot F, Dulucq S, Rousselot P, Guilhot J (2013) Preliminary Report Of The STIM2 Study: a multicenter Stop Imatinib trial for chronic phase chronic myeloid leukemia de novo patients on imatinib. Blood (ASH Annual Meeting Abstracts) [abstract 654]

  16. Rousselot P, Charbonnier A, Cony-Makhoul P et al (2014) Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 32:424–430

    Article  CAS  PubMed  Google Scholar 

  17. Saussele S, Richter J, Guilhot J, Müller MC, Dietz C, Porkka K et al (2014) First interim analysis of a Pan-European Stop trial using standardized molecular criteria: results of the EURO-SKI trial. 19th Congress of the European Hematology Association, Milan, Italy, June 12–15, 2014. Haematologica 99(supl. 1):LB-6214

    Google Scholar 

  18. Mahon FX, Baccarani M, Mauro M et al (2014) Treatment-free remission following nilotinib in patients with chronic myeloid leukemia in chronic phase: ENESTfreedom, ENESTop, ENESTgoal, and ENESTpath ASCO meeting 2014. J Clin Oncol 32:5s, (suppl; abstr TPS7124)

  19. Stein AM, Bottino D, Modur V et al (2011) BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clin Cancer Res 21:6812–6821

    Article  Google Scholar 

  20. Horn M, Glauche I, Müller MC, Hehlmann R, Hochhaus A, Loeffler M, Roeder I (2013) Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Blood 121:378–384

    Article  CAS  PubMed  Google Scholar 

  21. Cross NCP, White H, Müller MC, Saglio G, Hochhaus A (2012) Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 26(10):2172–2175

    Article  CAS  PubMed  Google Scholar 

  22. Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K et al (2007) BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clin Cancer Res 13:7080–7085

    Article  CAS  PubMed  Google Scholar 

  23. Melo JV, Ross DM (2011) Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure? Hematol Am Soc Hematol Educ Program 2011:136–142

    Article  Google Scholar 

  24. Biernaux C, Loos M, Sels A et al (1995) Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals. Blood 8:3118–3122

    Google Scholar 

  25. Bose S, Deininger M, Gora-Tybor J et al (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92:3362–3367

    CAS  PubMed  Google Scholar 

  26. Deininger M (2011) Hematology: curing CML with imatinib—a dream come true? Nat Rev Clin Oncol 3:127–128

    Article  Google Scholar 

  27. Réa D, Rousselot P, Nicolini F, Legros L, Tulliez M, Giraudier S, Cony-Makhoul P, Guilhot F, Mahon FX (2011) Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia patients with stable undetectable BCR-ABL transcripts: results from the French CML group (FI-LMC) Blood (ASH) 2012: Abstract 9168. Rea D, et al. Blood.;118(21) [abstract 604]

  28. Yhim HY, Lee NR, Song EK, Yim CY, Jeon SY, Shin S et al (2012) Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response. Leuk Res 36:689–693

    Article  CAS  PubMed  Google Scholar 

  29. Branford S, Yeung DT, Ross DM et al (2013) Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood 121:3818–3824

    Article  CAS  PubMed  Google Scholar 

  30. Falchi L, Kantarjian HM, Wang X et al (2013) Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88:1024–1029

    Article  CAS  PubMed  Google Scholar 

  31. Hehlmann R, Müller MC, Lauseker M et al (2014) Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol 32:415–423

    Article  PubMed  Google Scholar 

  32. Rea D, Dulphy N, Henry G, J Guilhot J, Guilhot F, Franck E. Nicolini, Legros L, Rousselot Ph, Mahon FX, Toubert A (2013) Low natural killer (NK) cell counts and functionality are associated with molecular relapse after imatinib discontinuation in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) with undetectable BCR-ABL transcripts for at least 2 years: preliminary results from immunostim, on behalf of STIM investigators. Blood (ASH Annual Meeting Abstracts); 122 (suppl): [abstract 856)

  33. Ilander MM, Olsson-Strömberg U, Lähteenmäki H et al (2013) Disease Relapse After TKI Discontinuation in CML is related both To low number and impaired function of NK-cells: data from Euro-SKI. Blood (ASH Annual Meeting Abstracts); 122 (suppl): [abstract 379)

  34. Mahon FX, Delbrel X, Cony-Makhoul P et al (2002) Follow-up of complete cytogenetic remission in patients with chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214–220

    Article  CAS  PubMed  Google Scholar 

  35. Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47:1–7

    Article  CAS  PubMed  Google Scholar 

  36. Gallipoli P, Abraham SA, Holyoake TL (2011) Hurdles toward a cure for CML: the CML stem cell. Hematol Oncol Clin N Am 25:951–966

    Article  Google Scholar 

  37. Rea D, Rousselot P, Guilhot J et al (2012) Curing chronic myeloidleukemia. Curr Hematol Malignancy Rep 7:103–108

    Article  Google Scholar 

  38. Hantschel O, Warsch W, Eckelhart E et al (2012) BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia. Nat Chem Biol 8:285–293

    Article  CAS  PubMed  Google Scholar 

  39. Chen Y, Peng C, Sullivan C et al (2010) Novel therapeutic agents against cancer stem cells of chronic myeloid leukemia. Anti Cancer Agents Med Chem 10:111–115

    Article  CAS  Google Scholar 

  40. Zhang B, Strauss AC, Chu S et al (2010) Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell 17:427–442

    Article  PubMed Central  PubMed  Google Scholar 

  41. Li L, Wang L, Li L et al (2012) Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21:266–281

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  42. Hurtz C, Hatzi K, Cerchietti L et al (2011) BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. J Exp Med 208:2163–2174

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. Kleppe M, Levine RL (2012) Targeting beta-catenin in CML: leukemiastem cells beware! Cell Stem Cell 10:351–353

    Article  CAS  PubMed  Google Scholar 

  44. Dierks C, Beigi R, Guo GR et al (2008) Expansion of Bcr-Ablpositive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell 14:238–249

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest for the current work.

Author information

Authors and Affiliations

  1. Laboratoire d’hématologie, CHU de Bordeaux, Bordeaux, France

    Francois-Xavier Mahon

  2. Laboratoire Hématopoïèse Leucémique et Cible Thérapeutique, INSERM 1035, Université Bordeaux, 146 Rue Léo Saignat, 33076, Bordeaux Cedex, France

    Francois-Xavier Mahon

Authors
  1. Francois-Xavier Mahon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francois-Xavier Mahon.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mahon, FX. Discontinuation of tyrosine kinase therapy in CML. Ann Hematol 94 (Suppl 2), 187–193 (2015). https://doi.org/10.1007/s00277-015-2320-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-015-2320-4

Keywords

Search

Navigation